Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?
暂无分享,去创建一个
T. Mok | Jin-Ji Yang | Tony Mok | Jin-Ji Yang | Kwok-Chi Lam | K. Lam
[1] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[2] K. Hagiwara,et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp , 2006, British Journal of Cancer.
[3] T. Kijima,et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. , 2004, Clinical lung cancer.
[4] A. Rossi,et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. , 2003, Journal of the National Cancer Institute.
[5] T. Mok,et al. Brain Metastasis Responding to Gefitinib Alone , 2004, Oncology.
[6] S. Kudoh,et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) , 2008, British Journal of Cancer.
[7] S. Ameshima,et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. , 2011, Clinical Lung Cancer.
[8] P. Jänne,et al. Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? , 2008, Clinical Cancer Research.
[9] F. Cappuzzo,et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] I. Iwanicki-Caron,et al. Cytologic and molecular characterizations of CTC detected in patients with metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] F. Hirsch,et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Young Tae Kim,et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Nexo,et al. Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] Koichi Yamazaki,et al. Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations , 2009, Clinical Cancer Research.
[15] Mayumi Ono,et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.
[16] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[17] G. Luporini,et al. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.
[18] T. Oyama,et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. , 2009, Lung Cancer.
[19] C. García-Girón,et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[21] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[22] M. Fukuoka,et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Chun-Ming Tsai,et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Thomas J. Smith,et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Thiberville,et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[28] Dae-Ho Lee,et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. , 2012, Lung Cancer.
[29] M. Rinaldi,et al. Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases , 2007, Cancer.
[30] J. Sculier. Nonsmall cell lung cancer , 2013, European Respiratory Review.
[31] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[32] Hyae-Young Kim,et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Dennie V. Jones,et al. Response of intracranial metastases to erlotinib therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] L. Sequist,et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. , 2010, Neuro-oncology.
[35] I. Sohn,et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. , 2010, Lung cancer.
[36] H. Bai,et al. Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer. , 2011, Journal of Clinical Oncology.
[37] Jie Yang,et al. Health-Related Quality-of-Life in a Randomized Phase III First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[38] T. Mok,et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Jung-Il Lee,et al. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? , 2010, Lung cancer.
[40] A. Gemma,et al. F1000 highlights , 2010 .
[41] T. Mok,et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. , 2012 .
[42] V. Guillem,et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation , 2010, European Respiratory Journal.
[43] S. Matsusaka,et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. , 2012, Journal of Clinical Oncology.
[44] M. Pan,et al. CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation , 2007, Nature Clinical Practice Oncology.
[45] A. Miyamoto,et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. , 2010, Internal medicine.
[46] Pedro Mendez,et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. , 2005, Lung cancer.
[47] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[48] J. Whang‐Peng,et al. Phase II randomized trial of erlotinib versus vinorelbine in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) aged ≥70 years in Taiwan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Edward S. Kim,et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] A. Gemma,et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Nevins,et al. Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Yi-long Wu,et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Heung Tae Kim,et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first , 2008, Cancer.
[54] S. Toyooka,et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). , 2012 .
[55] L. Sequist,et al. Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance. , 2012 .
[56] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[57] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[58] D. Gandara,et al. Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.